Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Patients who died from COVID-19 often had comorbidities, such as hypertension, diabetes, and chronic obstructive lung disease. Although angiotensin-converting enzyme 2 (ACE2) is crucial for SARS-CoV-2 to bind and enter host cells, no study has systematically assessed the ACE2 expression in the lungs of patients with these diseases. Here, we analyzed over 700 lung transcriptome samples from patients with comorbidities associated with severe COVID-19 and found that ACE2 was highly expressed in these patients compared to control individuals. This finding suggests that patients with such comorbidities may have higher chances of developing severe COVID-19. Correlation and network analyses revealed many potential regulators of ACE2 in the human lung, including genes related to histone modifications, such as HAT1, HDAC2, and KDM5B. Our systems biology approach offers a possible explanation for increased COVID-19 severity in patients with certain comorbidities.

Original publication




Journal article


J Infect Dis

Publication Date





556 - 563


COVID-19, KDM5B, SARS-CoV-2, angiotensin converting enzyme 2, Angiotensin-Converting Enzyme 2, COVID-19, Case-Control Studies, Cerebrovascular Disorders, Comorbidity, Coronary Disease, Coronavirus Infections, Diabetes Complications, Epigenomics, Female, Humans, Hypertension, Lung, Male, Pandemics, Peptidyl-Dipeptidase A, Pneumonia, Viral, Pulmonary Disease, Chronic Obstructive, Severity of Illness Index, Systems Biology, Transcriptome